CN102309448A - Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof - Google Patents
Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN102309448A CN102309448A CN201010212441XA CN201010212441A CN102309448A CN 102309448 A CN102309448 A CN 102309448A CN 201010212441X A CN201010212441X A CN 201010212441XA CN 201010212441 A CN201010212441 A CN 201010212441A CN 102309448 A CN102309448 A CN 102309448A
- Authority
- CN
- China
- Prior art keywords
- peg
- ciprofloxacin
- liposome
- compositions according
- phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention belongs to the field of drugs and pharmaceutics and relates to a pulmonary delivery ciprofloxacin pharmaceutical composition. In particular, a liposome modified by PEG (Polyethylene Glycol) is used as a drug carrier in the composition; the liposome modified by the PEG is that PEG molecules are directly connected to the liposome; or the liposome is coated by the PEG molecules. The invention further relates to the preparation method of the composition. According to the composition disclosed by the invention, the stability is good; the action time is prolonged; the better antibacterial effect is obtained; furthermore, the pulmonary effective treatment concentration can be achieved rapidly; the bioavailability is high; the composition is convenient to carry; and the composition can be taken independently.
Description
Technical field
The invention belongs to medicine and pharmaceutics field, relate to ciprofloxacin Pharmaceutical composition of a kind of pulmonary administration and preparation method thereof.
Background technology
Ciprofloxacin is a third generation carbostyril family antibacterial drugs, many characteristics such as tool has a broad antifungal spectrum, antimicrbial power are strong, simple in structure, convenient drug administration.It is through acting on the A subunit of DNA of bacteria helicase, suppresses the synthetic of DNA and duplicates and cause bacterial death.Ciprofloxacin has broad-spectrum antibacterial action, and is very strong to the antibacterial activity of gram negative bacteria.Following antibacterial is had a good antibacterial action external: most of antibacterial of enterobacteriaceae comprises that citrobacter belongs to Enterobacters such as cloaca, clostridium perfringen; Escherichia coli, Klebsiella, Proteus; Salmonella, Shigella, vibrio and Ye Ersen Pseudomonas etc.Multi-drug resistant bacteria also had antibacterial activity, as the drug-fast NEISSERIA GONORRHOEAE of penicillin, product enzyme hemophilus influenza and Moraxella all there being the antibacterial activity of height.Most of bacterial strain tool antibacterial actions to Pseudomonas aeruginosa Rhodopseudomonass such as (bacillus pyocyaneus that promptly is commonly called as).The staphylococcus of methicillin-sensitivity is also had an antibacterial activity, to streptococcus pneumoniae, Hemolytic streptococcus and the medium antibacterial activity of enterococcus faecalis tool.To chlamydia trachomatis, mycoplasma, anti-microbial effect that the legionella tool is good, mycobacterium and atypical mycobacteria also there is antibacterial activity; Antibacterial activity to anaerobe is then relatively poor.
The onset of ciprofloxacin oral administration is slow, drug administration by injection patient poor compliance.And that pulmonary administration has a sorbent surface is long-pending big, and the absorption site blood flow is abundant, avoids the first pass effect of liver,, enzymatic activity is low, and therefore characteristics such as the thin and membrane permeability height of epithelium barrier, can reach pulmonary effectively to treat concentration fast, and bioavailability is high.Pulmonary's inhalation novel form mainly contains aerosol, spray and powder spray, and that inhalation has is easy to use, onset characteristics rapidly.Powder spray has overcome drug release and has sucked inharmonic problem for breathing initiatively.
Liposome has following characteristics as the carrier of pulmonary administration: alveolar surfactant mainly is made up of phospholipid, and main component is a dipalmitoyl phosphatidyl choline.Liposome is to be formed by phospholipid bilayer equally, and is identical with the pulmonary endogenous material, thereby both have good biocompatibility; In topical therapeutic, make medicine directly act on target spot, rapid-action, dosage is low, long action time, it is few to get into body circulation medication amount, side effect is low; Medicine can reduce drug toxicity with after liposomal encapsulated, alleviates local excitation and injury of lung behind the pulmonary administration.
Existing Canadian document discloses the preparation (Desai that a kind of ciprofloxacin liposome is used for pulmonary's inhalation; T.R.et al.2003.Delivery of liposomes in drypowder form:a erodynamic dispersion properties.Eur.J.Pharm.Sci.20,459-467; Jonathan P.Wong; Et al.2003.Liposomedelivery of ciprofloxacin against intracellular Francisellatularensis infection.Journal of Controlled Release.92; 265-273.); It is by after lecithin or dipalmitoyl phosphatidyl choline and the cholesterol preparation formation ciprofloxacin liposome; The powder that the spraying lyophilizing makes mixes with lactose; Process pulmonary's Foradil Aerolizer formoterol fumarate or directly the ciprofloxacin liposome is processed spray (Lyle G.Sweeney et al.2005.Spray-freeze-dried liposomal ciprofloxacin powder for inhaledaerosol drug deliveryInternational Journal ofPharmaceutics.305,180-185; Tejas R.Desai et al.2001.Determination of surface free energy of interactive dry powderliposome formulations using capillary penetration technique.Colloids and Surfaces B:Biointerfaces.22,107-113; W.H.Finlay, J.P.Wong, 1998, Regional lung deposition of nebulizediposome-encapsulated iprofloxacin.International Journal ofPharmaceutics.167,121-127.).The liposome that this method makes is stable inadequately, is prone to take place the seepage of liposome, and then influences the quality of the pharmaceutical preparations.
The present invention to improve the stability of liposome, prolongs action time through phospholipid material directly being connected the PEG molecule or with PEG molecule coating liposome, obtaining the liposome of PEGization.The present invention adds absorption enhancer simultaneously, reduces pulmonary's clearance rate, and the pulmonary that is beneficial to ciprofloxacin absorbs.
Summary of the invention
One aspect of the present invention relates to a kind of ciprofloxacin Pharmaceutical composition of pulmonary administration, and its liposome of modifying with PEG is as the carrier of ciprofloxacin.Particularly, to be the PEG molecule combines the back to prepare liposome through covalent bond with nitrogenous base on the phospholipid molecule to the liposome that said PEG modifies, and perhaps will prepare the gained liposome and be injected into formation coating liposome in the PEG solution.
In one embodiment of the invention, said PEG is PEG1500, PEG2000 or PEG4000, particularly, is PEG2000.
In one embodiment of the invention, said ciprofloxacin is ciprofloxacin or ciprofloxacin lactate, particularly, is ciprofloxacin.
In one embodiment of the invention; Said liposome is the complex that phospholipid or itself and other material are connected to form; Said phospholipid is selected from one or more in lecithin phatidylcholine (EPC), dipalmitoyl phosphatidyl choline (DPPC), two nutmeg phosphatidyl cholines (DMPC), the two nutmeg acyl phosphatidyl glycerols (DMPG), and said complex is selected from one or more among EPC-PEG, DPPC-PEG, DMPC-PEG, the DMPG-PEG.Said other material can be, for example, and cholesterol.The mol ratio of said ciprofloxacin and phospholipid and/or phosphatide complexes is 1/1 to 1/10, particularly, is 1/5.
In one embodiment of the invention, said compositions is aerosol, spray or powder spray, particularly, is powder spray.
In one embodiment of the invention, said compositions also comprises propellant, cosolvent, surfactant, absorption enhancer or excipient.
In one embodiment of the invention; Said propellant is tetrafluoroethane (HFA134a) and/or heptafluoro-propane (HFA227); Said cosolvent is ethanol and/or propylene glycol; Said surfactant is selected from one or more in Tween 80, sorbester p37, oleic acid, the phosphatidylcholine, and said absorption enhancer is selected from one or more in sodium cholate, sodium caprylate, Brij 78, the rare earth compound Gadolinium trichloride.
In one embodiment of the invention, said excipient is selected from lactose, mannitol, aminoacid or phospholipid, particularly, is lactose, and the mass ratio of said ciprofloxacin and excipient lactose is 1/3 to 1/10, and preferred 1/5.
In one embodiment of the invention, the particle size range of said compositions is 100 μ m to 200 μ m, particularly, is 150 μ m.The present invention measures the granularity of lactose through using nano particle size and Zeta potential and molecular weight analyse appearance, and selecting its particle size range is 100 μ m to 200 μ m, and preferred 150 μ m are to reach the demand of lactose as the powder spray carrier.
Also aspect of the present invention relates to above-mentioned preparation of compositions method; Comprise the PEG molecule is combined back refabrication liposome through covalent bond with nitrogenous base on the phospholipid molecule, perhaps will prepare the gained liposome and be injected into formation coating liposome in the PEG solution.
The beneficial effect of the invention
1) it is stable inadequately that compositions of the present invention has overcome in the ciprofloxacin compositions of existing pulmonary administration liposome; Be prone to take place the deficiency of liposome seepage; The good stability of compositions (comprising the liposome in the compositions), and prolonged action time, obtained better antibacterial effect;
2) it is slow that the present invention has overcome the onset of ciprofloxacin oral administration, and the shortcoming of drug administration by injection patient poor compliance can reach pulmonary fast and effectively treat concentration, and bioavailability is high, and easy to carry, independently medication.
The specific embodiment
To combine embodiment that embodiment of the present invention are described in detail below, but it will be understood to those of skill in the art that the following example only is used to explain the present invention, and should not be regarded as limiting scope of the present invention.Unreceipted actual conditions person among the embodiment carries out according to the condition of normal condition or manufacturer's suggestion.The unreceipted person of production firm of agents useful for same or instrument, being can be through the conventional products of commercial acquisition.
Embodiment 1: the preparation of control sample
Prepare control sample with reference to following document:
Tejas?R.Desai?et?al.2001.Determination?of?surface?freeenergy?of?interactive?dry?powder?liposome?formulations?usingcapillary?penetration?technique.Colloids?and?Surfaces?B：Biointerfaces.22，107-113；W.H.Finlay，J.P.Wong，1998，Regional?lung?deposition?of?nebulized?iposome-encapsulatediprofloxacin.International?Journal?of?Pharmaceutics.167，121-127.
Particularly, prescription is as follows:
Ciprofloxacin 0.11g
DPPC 0.55g
Cholesterol 0.45g
Lactose 2.2g
0.6M ammonium sulfate solution 20ml
Method for preparing: DPPC and the cholesterol of getting recipe quantity are dissolved in the chloroform reduction vaporization; With the ammonium sulfate hydration of 0.6M, ultrasonic granulate is with a certain amount of normal saline dialysis 12h; The medicine that adds recipe quantity; 50 ℃ of water-baths hatching 5min process superfine powder after the lyophilizing, powder and the lactose mix homogeneously special container of packing into is promptly got sample 1.
Embodiment 2: the preparation of spray dosage form sample of the present invention
Write out a prescription as follows:
Ciprofloxacin 0.11g
DPPC-PEG2000 0.55g
Cholesterol 0.45g
Tween 80 0.1ml
0.6M ammonium sulfate solution 20ml
Method for preparing: DPPC-PEG2000 and the cholesterol of getting recipe quantity are dissolved in the chloroform reduction vaporization, and with the ammonium sulfate hydration of 0.6M, ultrasonic granulate with a certain amount of normal saline dialysis 12h, adds the medicine of recipe quantity, 50 ℃ of water-bath hatching 5min.This sample and Tween 80 mix homogeneously packed into promptly get sample 2 in the specific spray bottle.
Embodiment 3: the preparation of aerosol dosage forms sample of the present invention
Write out a prescription as follows:
Ciprofloxacin 0.11g
DPPC-PEG2000 0.55g
Cholesterol 0.45g
Tween 80 0.1ml
Tetrafluoroethane (HFA134a) 3ml
0.6M ammonium sulfate solution 20ml
Make method: DPPC-PEG2000 and the cholesterol of getting recipe quantity are dissolved in the chloroform reduction vaporization, and with the ammonium sulfate hydration of 0.6M, ultrasonic granulate with a certain amount of normal saline dialysis 12h, adds the medicine of recipe quantity, 50 ℃ of water-bath hatching 5min.This sample and Tween 80 mix homogeneously are packed into after the special container, and the filling tetrafluoromethane promptly gets sample 3.
Embodiment 4: the preparation of powder spray dosage form sample of the present invention
Write out a prescription as follows:
Ciprofloxacin 0.11g
DPPC-PEG2000 0.55g
Cholesterol 0.45g
0.6M ammonium sulfate solution 20ml
Lactose 2.2g
Method for preparing: DPPC-PEG2000 and the cholesterol of getting recipe quantity are dissolved in the chloroform reduction vaporization; With the ammonium sulfate hydration of 0.6M, ultrasonic granulate is with a certain amount of normal saline dialysis 12h; The medicine that adds recipe quantity; 50 ℃ of water-baths hatching 5min process superfine powder after the spraying lyophilizing, and powder and the lactose mix homogeneously special container of packing into is promptly got sample 4.
Embodiment 5: the streptococcus pneumoniae antibacterial tests
1. material therefor and reagent
Animal: Kunming mouse body weight 18-22g, male and female half and half.
Bacterial strain: streptococcus pneumoniae.
Receive the reagent group: administration is a sample 4.
Matched group: administration is a sample 1.
Streptococcus pneumoniae group: give normal saline.
2. test method
(1) mensuration of the MLD of bacterial strain: the clinical isolates strain is incubated on the broth bouillon in test the previous day; Process certain density bacteria suspension with 5% yeast soln, it is some to get mice, lumbar injection 5% yeast; The streptococcus pneumoniae of variable concentrations; Volume injected is 0.5ml/, writes down the animal dead number in a week, finds out the MLD of above-mentioned animal dead.The MLD that records streptococcus pneumoniae is 10
6/ ml.
(2) antibacterial tests: get 110 mices, body weight 18-22g, male and female half and half are divided into 11 groups at random, 10 every group.The present invention is received reagent group and positive control drug group, give medicine preceding four days of infection through the inhalation device, be administered once every day, totally four days.Streptococcus pneumoniae abdominal cavity infection amount is 10
6Individual/above-mentioned 5% yeast soln of milliliter is processed certain density bacteria suspension.Observed for 1 week then, record animals survived situation is calculated ED
50And 95% fiducial limit.
3. antibacterial tests result
Table 1: to the The anti-bacterial result of streptococcus pneumoniae infection mice
The result of table 1 shows that the present invention has the effect of anti-streptococcus pneumoniae, and its antibacterial effect is superior to contrasting medicine.
Embodiment 6: the staphylococcus aureus antibacterial tests
In the present embodiment,, the same among all the other test materials and method and the embodiment 5 except bacterial strain uses therefor is a staphylococcus aureus.The MLD that records staphylococcus aureus is 10
6Individual/ml.The infection of staphylococcus aureus amount is 10
6Individual/ml.The result is shown in following table 2.
Table 2: to the The anti-bacterial result of infection of staphylococcus aureus mice
The result of table 2 shows that the present invention has the effect of anti-infection of staphylococcus aureus, and effect is superior to contrasting medicine.
Embodiment 7: uncle pneumobacillus antibacterial tests
In the present embodiment,, the same among all the other test materials and method and the embodiment 5 except bacterial strain uses therefor is the uncle pneumobacillus.The MLD that records the uncle pneumobacillus is 10
5Individual/ml.Uncle pneumobacillus infective dose is 10
5Individual/ml.The result is shown in following table 3.
Table 3: to the The anti-bacterial result of uncle pneumobacillus infecting mouse
The result of table 3 shows, the effect that the present invention has anti-uncle pneumobacillus to infect, and effect is superior to contrasting medicine.
Although the specific embodiment of the present invention has obtained detailed description, it will be understood to those of skill in the art that.According to disclosed all instructions, can carry out various modifications and replacement to those details, these change all within protection scope of the present invention.Four corner of the present invention is provided by accompanying claims and any equivalent thereof.
Claims (10)
1. the ciprofloxacin Pharmaceutical composition of a pulmonary administration, its liposome of modifying with PEG is as the carrier of ciprofloxacin.
2. compositions according to claim 1, wherein, the liposome that said PEG modifies is that the PEG molecule is combined back refabrication liposome through covalent bond with phospholipid molecule, perhaps uses PEG coating liposome.
3. compositions according to claim 1, wherein said PEG is PEG1500, PEG2000 or PEG4000, particularly, is PEG2000.
4. compositions according to claim 1, wherein, said ciprofloxacin is ciprofloxacin or ciprofloxacin lactate, particularly, is ciprofloxacin.
5. compositions according to claim 1; Wherein, Said liposome is the complex that phospholipid or itself and other material are connected to form; Said phospholipid is selected from one or more in lecithin phatidylcholine (EPC), dipalmitoyl phosphatidyl choline (DPPC), two nutmeg phosphatidyl cholines (DMPC), the two nutmeg acyl phosphatidyl glycerols (DMPG), and said complex is selected from one or more among EPC-PEG, DPPC-PEG, DMPC-PEG, the DMPG-PEG, and the mol ratio of said ciprofloxacin and phospholipid and/or phosphatide complexes is 1/1 to 1/10; Particularly, be 1/5.
6. compositions according to claim 1, wherein, said compositions is aerosol, spray or powder spray, particularly, is powder spray.
7. compositions according to claim 1; It also comprises propellant, cosolvent, surfactant, absorption enhancer or excipient; Particularly; Said propellant is tetrafluoroethane (HFA134a) and/or heptafluoro-propane (HFA227); Said cosolvent is ethanol and/or propylene glycol, and said surfactant is selected from one or more in Tween 80, sorbester p37, oleic acid, the phosphatidylcholine, and said absorption enhancer is selected from one or more in sodium cholate, sodium caprylate, Brij 78, the rare earth compound Gadolinium trichloride.
8. compositions according to claim 7, said excipient is selected from lactose, mannitol, aminoacid or phospholipid, particularly, is lactose, and the mass ratio of said ciprofloxacin and excipient lactose is 1/3 to 1/10, and preferred 1/5.
9. compositions according to claim 8, wherein, the particle size range of said compositions is 100 μ m to 200 μ m, particularly, is 150 μ m.
10. the described preparation of compositions method of claim 1 comprises the PEG molecule and perhaps to use the step of PEG coating liposome through the covalent bond back preparation liposome that is connected with phospholipid molecule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010212441.XA CN102309448B (en) | 2010-06-29 | 2010-06-29 | Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010212441.XA CN102309448B (en) | 2010-06-29 | 2010-06-29 | Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102309448A true CN102309448A (en) | 2012-01-11 |
| CN102309448B CN102309448B (en) | 2014-07-09 |
Family
ID=45423271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010212441.XA Active CN102309448B (en) | 2010-06-29 | 2010-06-29 | Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102309448B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015157038A1 (en) | 2014-04-08 | 2015-10-15 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| CN105232464A (en) * | 2015-11-11 | 2016-01-13 | 郑州后羿制药有限公司 | Hydrochloric acid ciprofloxacin lipidosome preparation and preparation method thereof |
| CN113456590A (en) * | 2021-07-22 | 2021-10-01 | 药大制药有限公司 | Salbutamol lipid aerosol |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO2001015750A1 (en) * | 1999-08-27 | 2001-03-08 | Department Of National Defence | Hydrogel wound dressing containing liposome-encapsulated therapeutic agent |
| CN1295465A (en) * | 1998-04-02 | 2001-05-16 | 阿尔扎有限公司 | Quinolone-containing liposome composition |
| CN1351495A (en) * | 1999-04-29 | 2002-05-29 | 阿尔萨公司 | Liposome compositions for improved drugretention |
| CN101095659A (en) * | 2006-06-28 | 2008-01-02 | 蔡海德 | Liposome combined medicine and method for preparing the same |
| CN101401790A (en) * | 2008-11-14 | 2009-04-08 | 山东大学 | Lavo-ofloxacin liposome and preparation method thereof |
| CN101553209A (en) * | 2006-10-24 | 2009-10-07 | 阿拉迪姆公司 | Dual action, inhaled formulations providing both an immediate and sustained release profile |
-
2010
- 2010-06-29 CN CN201010212441.XA patent/CN102309448B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| CN1295465A (en) * | 1998-04-02 | 2001-05-16 | 阿尔扎有限公司 | Quinolone-containing liposome composition |
| CN1351495A (en) * | 1999-04-29 | 2002-05-29 | 阿尔萨公司 | Liposome compositions for improved drugretention |
| WO2001015750A1 (en) * | 1999-08-27 | 2001-03-08 | Department Of National Defence | Hydrogel wound dressing containing liposome-encapsulated therapeutic agent |
| CN101095659A (en) * | 2006-06-28 | 2008-01-02 | 蔡海德 | Liposome combined medicine and method for preparing the same |
| CN101553209A (en) * | 2006-10-24 | 2009-10-07 | 阿拉迪姆公司 | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| CN101401790A (en) * | 2008-11-14 | 2009-04-08 | 山东大学 | Lavo-ofloxacin liposome and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 周建平: "《药剂学》", 31 March 2007, 东南大学出版社 * |
| 王志宣等: "脂质体肺部给药系统的应用", 《中国医药工业杂志》 * |
| 王绍宁等: "盐酸环丙沙星脂质体的制备及小鼠体内分布", 《中国药学杂志》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015157038A1 (en) | 2014-04-08 | 2015-10-15 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| EP3129004A4 (en) * | 2014-04-08 | 2017-11-15 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| US10376508B2 (en) | 2014-04-08 | 2019-08-13 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| AU2015244275B2 (en) * | 2014-04-08 | 2019-08-29 | Aradigm Corporation | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| US11116765B2 (en) | 2014-04-08 | 2021-09-14 | Grifols, S.A. | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria |
| CN105232464A (en) * | 2015-11-11 | 2016-01-13 | 郑州后羿制药有限公司 | Hydrochloric acid ciprofloxacin lipidosome preparation and preparation method thereof |
| CN113456590A (en) * | 2021-07-22 | 2021-10-01 | 药大制药有限公司 | Salbutamol lipid aerosol |
| CN113456590B (en) * | 2021-07-22 | 2023-02-03 | 药大制药有限公司 | Salbutamol lipid aerosol |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102309448B (en) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cipolla et al. | Lipid-based carriers for pulmonary products: preclinical development and case studies in humans | |
| Bassetti et al. | Inhaled liposomal antimicrobial delivery in lung infections | |
| US11116765B2 (en) | Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria | |
| d'Angelo et al. | Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies | |
| Drulis-Kawa et al. | Liposomes as delivery systems for antibiotics | |
| Khuller et al. | Liposome technology for drug delivery against mycobacterial infections | |
| Willis et al. | Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery | |
| JP5797217B2 (en) | Dual-action inhalation formulation providing both immediate release and sustained release properties | |
| Bakker-Woudenberg et al. | Long-circulating sterically stabilized liposomes in the treatment of infections | |
| BRPI0613865A2 (en) | sustained release of antiinfectives | |
| US6613352B2 (en) | Low-rigidity liposomal formulation | |
| CN112004527A (en) | Inhalable liposome sustained-release composition for treating pulmonary diseases | |
| Swaminathan et al. | Liposomes for pulmonary drug delivery | |
| AU2019324330A1 (en) | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them | |
| Woods et al. | Antimicrobial molecules in the lung: formulation challenges and future directions for innovation | |
| TWI230616B (en) | Liposome for incorporating large amounts of hydrophobic substances | |
| CN102309448B (en) | Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof | |
| Varma et al. | Formulation of host-targeted therapeutics against bacterial infections | |
| KR20090115856A (en) | Pharmaceutical composition comprising a campothecin derivative | |
| Ghosh et al. | Liposome-Based Antibacterial Delivery: An Emergent Approach to Combat Bacterial Infections | |
| CN114828828A (en) | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses comprising them and methods of treatment | |
| CN114040782A (en) | Transtympanic membrane delivery platform and uses thereof | |
| Nair et al. | Advanced drug delivery and therapeutic strategies for tuberculosis treatment | |
| US20210007985A1 (en) | Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm | |
| Alipour et al. | Liposome-entrapped antibiotics: recent progress and clinical applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |